Home > Riviste > Minerva Medica > Fascicoli precedenti > Minerva Medica 2016 August;107(4) > Minerva Medica 2016 August;107(4):245-50





Rivista di Medicina Interna

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236




Minerva Medica 2016 August;107(4):245-50

lingua: Inglese

Long noncoding RNA MALAT1 as a potential novel biomarker in digestive system cancers: a meta-analysis

Wei SONG, Run J. ZHANG, Shu B. ZOU

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China


INTRODUCTION: Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a newly discovered long non-coding RNA (lncRNA), has been reported to be overexpressed in various cancers. However, the clinical value of MALAT1 in digestive system cancers is unclear. This study was designed to investigate the potential value of MALAT1 as a prognostic biomarker in digestive system cancers.
EVIDENCE ACQUISITION: We searched the Medline, Embase and Cochrane Library databases. All studies that explored the correlation between lncRNA MALAT1 expression and survival in digestive system tumors were selected. A quantitative meta-analysis was performed for the correlation between lncRNA MALAT1 expression and survival in digestive system tumors.
EVIDENCE SYNTHESIS: Five studies were eligible for analysis, which included 547 patients. Meta-analysis showed that high expression of MALAT1 could predict poor overall survival (OS) in digestive system cancers (pooled HR: 1.85, 95% CI: 1.41-2.43, P<0.0001). For disease-free survival (DFS), elevated MALAT1 expression was also a significant predictor with a combined HR of 2.28 (95% CI: 1.42-3.67, P=0.0007).
CONCLUSIONS: lncRNA MALAT1 may serve as a potential novel prognostic biomarker in digestive system cancers.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail